UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 19, 2005
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
|
Massachusetts |
|
0-17999 |
|
04-2726691 |
|
(State or
other |
|
(Commission |
|
(IRS
Employer |
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
128 Sidney Street, Cambridge, MA 02139 |
||||
|
(Address of principal executive offices) (Zip Code) |
||||
|
|
|
|
|
|
|
Registrant’s telephone number, including area code: (617) 995-2500 |
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 – OTHER EVENTS
On April 19, 2005, ImmunoGen, Inc. issued a press release to announce the presentation of preclinical data on the Tumor-Activated Prodrug (TAP) compound AVE9633 (huMy9-6-DM4) at the American Association for Cancer Research (AACR) annual meeting in Anaheim, CA. ImmunoGen developed this CD33-targeting compound for the treatment of acute myeloid leukemia, and licensed it to the sanofi-aventis Group as part of a broader collaboration between the companies. The sanofi-aventis Group recently began clinical testing of AVE9633.
A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Exhibit |
|
|
|
|
|
99.1 |
|
Press Release of ImmunoGen, Inc. dated April 19, 2005 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ImmunoGen, Inc. |
|
|
|
|
|
(Registrant) |
||
|
|
|
|
||
|
Date: April 19, 2005 |
|
/s/ Karleen M. Oberton |
|
|
|
|
|
|
||
|
|
|
Karleen M. Oberton |
||
|
|
|
Senior Corporate Controller |
||
|
|
|
(Principal Accounting and Financial Officer) |
||
3